Regence – Commercial: Genetic Testing

Genetic Testing: effective May 1, 2021

• Genetic Testing for Hereditary Breast and Ovarian Cancer and LiFraumeni Syndrome (#02)
  • Added medical necessity criterion for germline BRCA1/2 testing if tumor testing indicates that a variant is present in the tumor tissue
• Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis in Patients with Breast Cancer (#42)
  • Added the use of the Breast Cancer Index for making decisions regarding extended endocrine therapy (beyond five years)
  • Made additional minor edits for clarity

Source: https://beonbrand.getbynder.com/m/75628f3dd274884f/original/2021-May-Bulletin.pdf